NO2106260T3 - - Google Patents

Info

Publication number
NO2106260T3
NO2106260T3 NO08700385A NO08700385A NO2106260T3 NO 2106260 T3 NO2106260 T3 NO 2106260T3 NO 08700385 A NO08700385 A NO 08700385A NO 08700385 A NO08700385 A NO 08700385A NO 2106260 T3 NO2106260 T3 NO 2106260T3
Authority
NO
Norway
Application number
NO08700385A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007902013A external-priority patent/AU2007902013A0/en
Application filed filed Critical
Publication of NO2106260T3 publication Critical patent/NO2106260T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO08700385A 2007-01-25 2008-01-25 NO2106260T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89776907P 2007-01-25 2007-01-25
AU2007902013A AU2007902013A0 (en) 2007-04-17 Inhibitory compounds
US98433507P 2007-10-31 2007-10-31
US737607P 2007-12-11 2007-12-11
PCT/AU2008/000089 WO2008089521A1 (en) 2007-01-25 2008-01-25 Insulin sensitisers and methods of treatment

Publications (1)

Publication Number Publication Date
NO2106260T3 true NO2106260T3 (cg-RX-API-DMAC10.html) 2018-05-05

Family

ID=39644028

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08700385A NO2106260T3 (cg-RX-API-DMAC10.html) 2007-01-25 2008-01-25

Country Status (12)

Country Link
US (3) US8455432B2 (cg-RX-API-DMAC10.html)
EP (1) EP2106260B8 (cg-RX-API-DMAC10.html)
JP (1) JP5301465B2 (cg-RX-API-DMAC10.html)
CN (1) CN101801375B (cg-RX-API-DMAC10.html)
AU (1) AU2008209320B2 (cg-RX-API-DMAC10.html)
CA (1) CA2676051C (cg-RX-API-DMAC10.html)
ES (1) ES2660170T3 (cg-RX-API-DMAC10.html)
NO (1) NO2106260T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ579229A (cg-RX-API-DMAC10.html)
PL (1) PL2106260T3 (cg-RX-API-DMAC10.html)
PT (1) PT2106260T (cg-RX-API-DMAC10.html)
WO (1) WO2008089521A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
US20200155558A1 (en) * 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ702666A (en) * 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction
BR112014029308A2 (pt) * 2012-05-24 2017-06-27 Verva Pharmaceuticals Ltd um método de melhorar a função hepática
AU2013202988B2 (en) * 2012-06-29 2016-04-21 NAIA Metabolic, Inc. Method of improving liver function
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2994701A (en) 1961-08-01 Z-sulfamyr
US2783241A (en) 1957-02-26 S-acylimino-x-substituted-az-i
US2554816A (en) 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
GB795174A (en) 1954-10-13 1958-05-21 Upjohn Co Heterocyclic sulphonamides
US2835702A (en) 1956-05-02 1958-05-20 Merck & Co Inc Benzene 1, 3 disulfonamides possessing diuretic properties
US2978457A (en) 1959-04-06 1961-04-04 Merck & Co Inc 5-acylamido-4-substituted-thiazole-2-sulfonamides having diuretic properties
US3157572A (en) 1961-01-06 1964-11-17 American Cyanamid Co Parenteral diuretic compositions of 5-acylimino-4-substituted-delta2-1, 3, 4-thiadiazolidine-2-sulfonamides
US3668248A (en) 1964-09-30 1972-06-06 Lilly Co Eli 5-chloro-2,4-bis(sulfamoyl)fluorobenzene and 5-chloro-2,4-bis(chlorosulfonyl)fluorobenzene
FR2468366A1 (fr) 1979-10-31 1981-05-08 Stoclet Alain Medicament antiglaucomateux a base d'acetazolamide ou de methazolamide
DE3377130D1 (en) 1982-05-28 1988-07-28 Ciba Geigy Ag Sulfonyl(thio)ureas, process for their preparation and their use as herbicides and/or growth regulating agents
IT1224860B (it) 1988-07-29 1990-10-24 Istituto Chimico Internazional Composti correlati all'acetozolammi de con attivita' inibitrice dell'anidrasi carbonica, utili in particolare nel trattamento del glaucoma
GB2223166B (en) 1988-09-29 1992-03-18 American Cyanamid Co Stable ophthalmic preparations containing methazolamide
US4990523A (en) 1989-06-19 1991-02-05 A. H. Robins Company, Incorporated Treatment of chronic inflammatory joint disease with arylsulfonamides
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5585377A (en) 1990-04-09 1996-12-17 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5225424A (en) 1992-10-21 1993-07-06 University Of Iowa Research Foundation Methazolamide-derived carbonic anhydrase inhibitors
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP0869785B1 (en) 1995-11-17 2002-08-28 PHARMACIA & UPJOHN COMPANY 4-hydroxycoumarin-3-carboxamides for the treatment of non-insulin dependent diabetes mellitus
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
GB9930688D0 (en) * 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
AU2382601A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel method of treatment
CA2415093A1 (en) 2000-07-07 2002-01-17 Carlos Plata-Salaman Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
WO2002013800A2 (en) 2000-08-11 2002-02-21 Einar Stefansson Method for the prevention and treatment of retinopathy
FR2816841B1 (fr) 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
US6800669B2 (en) 2000-12-22 2004-10-05 Dow Global Technologies Inc. Propylene copolymer foams
EP1695716A2 (en) 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
CA2364985A1 (en) 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
CA2516142A1 (en) 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
ES2385219T3 (es) * 2003-09-12 2012-07-19 Merck Serono Sa Derivados de sulfonamida para el tratamiento de diabetes
TW200533336A (en) 2004-03-02 2005-10-16 Fujisawa Pharmaceutical Co Concomitant drugs
RU2395503C2 (ru) 2004-05-19 2010-07-27 Зольвай Фармасьютиклз Гмбх Лекарственные средства, содержащие n-сульфамоил-n'-арилпиперазины, предназначенные для профилактики или лечения ожирения и связанных с ним состояний
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US20070110707A1 (en) * 2005-11-04 2007-05-17 Washington University Method of treating diseases involving non-enzymatic glycation
US7670794B2 (en) 2005-11-04 2010-03-02 Washington University Managing glycemia status in diabetic patients
TW200804393A (en) 2005-11-14 2008-01-16 Solvay Pharm Gmbh Novel N-sulfamoyl-N'-benzopyranpiperidines for medical use
JP2009515928A (ja) 2005-11-14 2009-04-16 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング カルボニックアンヒドラーゼの阻害剤としてのｎ−スルファモイル−ｎ’−ベンゾピランピペリジン
WO2007065948A1 (en) * 2005-12-09 2007-06-14 Solvay Pharmaceuticals Gmbh Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
WO2007114948A2 (en) 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
TW201105338A (en) 2009-07-01 2011-02-16 Kissei Pharmaceutical Medicine derived from a combination of SGLT1-inhibitor and DPP-IV inhibitor
CN103068400A (zh) 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
JP5722892B2 (ja) 2010-07-15 2015-05-27 武田薬品工業株式会社 複素環化合物
BR112014029308A2 (pt) 2012-05-24 2017-06-27 Verva Pharmaceuticals Ltd um método de melhorar a função hepática
NZ702666A (en) 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction

Also Published As

Publication number Publication date
US10172837B2 (en) 2019-01-08
US20140011848A1 (en) 2014-01-09
US20110003740A1 (en) 2011-01-06
CA2676051C (en) 2017-06-06
US9452148B2 (en) 2016-09-27
AU2008209320B2 (en) 2013-05-30
CA2676051A1 (en) 2008-07-31
EP2106260B1 (en) 2017-12-06
EP2106260B8 (en) 2018-04-04
EP2106260A4 (en) 2010-05-26
EP2106260A1 (en) 2009-10-07
CN101801375A (zh) 2010-08-11
JP5301465B2 (ja) 2013-09-25
ES2660170T3 (es) 2018-03-21
NZ579229A (en) 2011-07-29
CN101801375B (zh) 2014-01-01
WO2008089521A1 (en) 2008-07-31
PL2106260T3 (pl) 2018-06-29
US20170079960A1 (en) 2017-03-23
US8455432B2 (en) 2013-06-04
AU2008209320A1 (en) 2008-07-31
JP2010516711A (ja) 2010-05-20
PT2106260T (pt) 2018-03-05

Similar Documents

Publication Publication Date Title
BRPI0819773A2 (cg-RX-API-DMAC10.html)
CN300728994S (zh) 床头(3)
CN300778026S (zh) 包装盒(王者风范·男爵)
CN300743291S (zh) 茶叶包装纸(羽毛球)
CN300727351S (zh) 摩托车(426)
CN300730432S (zh) 童车(cdc-10)
CN300753103S (zh) 展架(易拉宝r113型)
CN300794196S (zh) 沙发(r162)
CN300730808S (zh) 蜡烛(72)
CN300728927S (zh) 桌子(9)
CN300807604S (zh) 型材(ymgr5303)
CN300848284S (zh) 羊绒衫(6852)
CN300728251S (zh) 冷暖风机(ac-1420)
CN300726207S (zh) 布(7)
CN300727238S (zh) 温控器
CN300726987S (zh) 包装盒(双氯芬酸钠)
CN300732632S (zh) 集成电源外壳(07-04)
CN300840765S (zh) 包装盒(长城1996)
CN300730782S (zh) 蜡烛(26)
CN300730745S (zh) 舞台灯具(变焦成像灯)
CN300889312S (zh) 开关(12)
CN300729928S (zh) 蓄电池盒(6-dzm-12b)
CN300729870S (zh) 金属轮毂(537)
CN300727132S (zh) 包装袋(田七纯棉洗衣粉)
CN300830675S (zh) 照相机透镜